Suzhou Basecare Medical Receives Landmark NMPA Approval for First Pre-implantation Thalassemia Genetic Testing Kit in China

Major Milestone with Class III Medical Device Registration for PGT-M Kit

Suzhou Basecare Medical Corporation Limited (Stock Code: 2170) announced a significant breakthrough for both the company and China’s reproductive health industry. On April 28, 2026, Basecare Medical secured the first-ever national Class III medical device registration certificate for its independently developed Pre-implantation Genetic Testing Kit for Thalassemia (Semiconductor Sequencing Method) (PGT-M Kit), registration number Guo Xie Zhu Zhun 20263400858 [[1]].

Key Highlights of the Announcement

• First-to-Market: The PGT-M Kit is the first pre-implantation thalassemia testing kit approved for market launch in China.
• Clinical Application: The kit is designed for qualitative detection of genomic DNA from trophectoderm cells of in vitro embryos as well as from both parents and/or relatives. It uses linkage analysis to determine whether embryos have inherited pathogenic thalassemia gene variants, enabling clinicians to select healthy embryos for transfer.
• Addressing a Major Public Health Issue: Thalassemia is a common autosomal recessive haemoglobinopathy in China, with approximately 30 million carriers nationwide and about 300,000 affected patients, growing at an annual rate of 10%. Risk is especially high in southern regions, making this kit highly relevant for clinical adoption [[1]].
• Strategic Market Gap Filled: This is the first domestically developed PGT-M product in China specifically targeting familial thalassemia prevention, closing a critical gap in the local market for home-grown pre-implantation genetic testing of monogenic disorders [[2]].

Market and Company Impact

• Supported by National R&D: The kit was included in China’s 14th Five-Year Plan key R&D initiative for reproductive health, emphasizing its strategic significance.
• Basecare’s Market Leadership: Basecare Medical currently commands over 50% market share of China’s PGT-compliant segment. The company has established collaborations with approximately 300 hospitals, co-founded over 60 joint laboratories, and maintains partnerships with more than 80 leading third-generation reproductive centers. Its product portfolio now includes PGT-A, PGT-M, and PGT-SR kits, with the new approval further broadening its offerings [[2]].
• Growth and Revenue Driver: Approval of the PGT-M Kit is expected to be a significant growth catalyst for the company’s genetic laboratory business. The new product is anticipated to materially contribute to future revenue and further solidify Basecare’s leadership in the third-generation IVF genetic testing market.

Strategic and Sector Implications

• National Support: China’s National Health Commission is advancing programs to strengthen birth-defect prevention and control. The PGT-M Kit provides a more precise and efficient pre-conception genetic testing tool, supporting national initiatives and clinical pathways for thalassemia and other hereditary diseases.
• Prevention Impact: The kit enables fundamental prevention of thalassemia gene transmission, helping affected families have healthy babies and reducing the incidence of birth defects across China.
• Shareholder Relevance: This approval is likely to be price-sensitive and could have a significant impact on the company’s share value due to its potential to drive both market share and future earnings.

Leadership Commentary

The announcement was made by Dr. Liang Bo, Chairman and General Manager, who emphasized the importance of this milestone for the company’s strategy and the broader Chinese healthcare sector. The board urges shareholders and potential investors to exercise caution in trading shares, considering the potential impact of this development on future performance.

Disclaimer: This article is for information purposes only and does not constitute investment advice. Investors should exercise caution and consult professional advisers before making investment decisions. The company’s future performance and share price may be affected by a range of factors, including but not limited to regulatory developments, market conditions, and operational outcomes.

View BASECARE-B Historical chart here